Balanced news tone
News Sentiment
CNTX sentiment intelligence
Context Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
57
Balanced news tone
48 relevant articles
News tone and price action are not far from neutral.
84/100 classification confidence.
directly relevant articles
high-authority source matches
-0.1% over one week, -53.0% over four weeks, trend inactive, and below fair value.
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – DUS:6K9
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
84/100 classification
One-week reaction
-0.1%
Price digesting
Trend fit
Trend inactive
-53.0% over four weeks
Fair value
-53.6%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
16
Neutral
30
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
GlobeNewswire
Direct company coverage
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
- Tone
- Positive 58/100
- Event
- Earnings
- Published
- 15 Jun 2026 10:30
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
Context Therapeutics Announces Positive Interim Efficacy
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Context Therapeutics (NASDAQ: CNTX) shows early CTIM-76 activity in platinum-resistant ovarian cancer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Stock Titan
GlobeNewswire
Direct company coverage
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 11:30
- Source
- GlobeNewswire
simplywall.st
Direct company coverage
Context Therapeutics Decline Means Insider Profits Down To US$237k
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 May 2026 07:00
- Source
- simplywall.st
MT Newswires
Direct company coverage
Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 18 May 2026 11:29
- Source
- MT Newswires
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Positive Signs As Multiple Insiders Buy Context Therapeutics Stock
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 27 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Market source
Direct company coverage
Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 05 Feb 2026 08:00
- Source
- Market source
simplywall.st
Direct company coverage
We're Hopeful That Context Therapeutics (NASDAQ:CNTX) Will Use Its Cash Wisely
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 19 Dec 2025 08:00
- Source
- simplywall.st
MarketBeat
Direct company coverage
Context Therapeutics (CNTX) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Oct 2021 23:22
- Source
- MarketBeat
Faegre Drinker Biddle & Reath LLP
Direct company coverage
Context Therapeutics Completes $25M IPO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Oct 2021 07:00
- Source
- Faegre Drinker Biddle & Reath LLP